John D. Yee - 31 Dec 2022 Form 5 Insider Report for Comera Life Sciences Holdings, Inc.

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA on OTC
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
5
Filing time
14 Feb 2023, 16:54:41 UTC
Previous filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Buy) Award +41,608 41,608 19 May 2022 Common Stock 41,608 $0.5900 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John D. Yee is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest in 48 equal monthly installments beginning on June 8, 2021.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company.

Remarks:

Exhibit 24 Power of Attorney filed herewith.